Researchers at Vanderbilt University Medical Center (VUMC) have received a four-year, $6.2-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a novel panel of biomarkers to improve the diagnosis of acute heart failure (AHF).

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

Up to 25% of patients with acute heart failure (AHF) face mortality or hospital readmission within one month after being treated in the emergency department (ED).

As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.

Sean Collins, MD, MSci, professor of Emergency Medicine, has taken on new leadership roles in the Vanderbilt Coordinating Center (VCC) and the Vanderbilt Institute for Medicine and Public Health (IMPH).

Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

A national study led by researchers at Vanderbilt University Medical Center has found that many patients who arrive at the emergency department (ED) with acute heart failure can be safely discharged with self-care guidance and frequent phone appointments, avoiding the need for hospitalization.